Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding

Biopharmaceutics & Drug Disposition

Volumn 16, Issue 6, 1995, Pages 443-460

  Edwards, D M F ^a,c   Pellizzoni, C ^a   Breuel, H P ^b   Berardi, A ^a   Castelli, M G ^a   Frigerio, E ^a   Poggesi, I ^a   Rocchetti, M ^a   Dubini, A ^a   Benedetti, M Strolin ^a  

^a PFIZER INC   (United States)

^b Afb Klinische Pharmakologie Gmbh Berlin Europa Centre ^*  (Germany)

^c SANOFI   (France)

Author keywords

antidepressants; pharmacokinetics; plasma protein binding

Indexed keywords

REBOXETINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; URINARY EXCRETION;

ADULT; ANTIDEPRESSIVE AGENTS; BLOOD PROTEINS; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HUMANS; MALE; MOLECULAR WEIGHT; MORPHOLINES; STEREOISOMERISM; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 0029094439     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.2510160603     Document Type: Article

References (22)

1. Potential antidepressant agents. α‐aryloxy‐benzyl derivatives of ethanolamine and morpholine
2. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies
3. Reboxetine prevents the tranylcypromine‐induced increase in tyramine levels in rat heart
4. Comparison of the effects of reboxetine and desipramine on the kinetic parameters of the pupillary light reflex in healthy volunteers
5. Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man
6. Configurational studies on 2‐(α‐(2‐ethoxyphenoxy)benzy)morpholine FCE 20124
7. A sensitive method for the quantitation of reboxetine enantiomers in human plasma by reversed‐phase HPLC with fluorimetric detection after chiral derivatisation with (+)‐1‐9‐(fluorenyl)ethyl chloroformate
8. 14C]reboxetine) a new antidepressant agent
9. The intellectual health of clinical drug evaluation
10. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
11. Pharmacokinetic optimisation of tricyclic antidepressant therapy
12. Comparative pharmacokinetic study of conventional and sustained‐release Viloxazine in normal volunteers
13. 1‐acid glycoprotein involvement in high affinity binding of tricyclic antidepressants to human plasma
14. Drug interactions with reversible monoamine oxidase‐A inhibitors